An international analysis based on individual patient data has validated the so-called Gold Coast criteria, a method designed to facilitate the diagnosis of amyotrophic lateral sclerosis (ALS) and promote earlier identification of the disease. This is «a key aspect to improve access to treatments, specialized care and clinical trials,» according to the researchers. The study, recently published in the scientific journal «Journal of Neurology«, was led by researchers from Adelaide University and the Brain and Nerve Research Centre of the University of Sydney (Australia).
The team of neurologists conducted a meta-analysis with individual patient data to assess the diagnostic accuracy of the Gold Coast criteria and compare it with that of other widely used systems, such as the revised El Escorial criteria and the Awaji criteria. The aim was to determine «whether the new approach makes it easier to identify people affected by ALS».
The revised El Escorial criteria are the classic system used for decades to diagnose ALS. They were developed by the World Federation of Neurology at a meeting held in El Escorial (Madrid) in the 1990s and later revised to improve their diagnostic performance.
And, on the other hand, the Awaji criteria emerged in 2008 as a practical modification of the El Escorial criteria. They were developed during a meeting of experts held on the Japanese island of Awaji with the aim of increasing the diagnostic sensitivity of ALS, especially in the early stages.
THE SIMPLICITY OF THE GOLD COAST
According to the authors, the Gold Coast criteria «were designed to simplify a traditionally complex diagnostic process.» Compared to previous models, which require classifications and diagnostic categories that are more difficult to apply, «this system seeks to offer a simpler and more practical tool for the neurologist.»
The Gold Coast criteria, developed and perfected by international experts since 2020, consider that a person can be diagnosed with ALS when they have a progressive deterioration of motor function, signs of damage to the neurons that control movement detected by clinical examination or electromyography and there is no other disease that better explains the clinical picture. Unlike previous diagnostic systems, they eliminate complex categories such as «possible,» «probable,» or «defined» ALS to «facilitate faster identification of patients.»
Lead authors of this recent work include Nipun Shrestha and Zachary Munn, from the School of Public Health at Adelaide University, and Steve Vucic, one of the world’s leading ALS specialists and a neurologist at the University of Sydney and Concord Hospital in New South Wales.
Specialists from leading institutions in Australia, Japan, Italy, Canada, China, the Netherlands, Belgium and Denmark also participated in the study, including Kyoto University, Chiba University, University of Brescia, University of Calgary, Peking Union Medical College Hospital, UMC Utrecht Brain Center and University Hospitals of Leuven.
The final report published stresses that ALS is a neurodegenerative disease «that progressively destroys the motor neurons responsible for controlling voluntary movements». Its symptoms usually begin with muscle weakness, problems walking, talking or swallowing and evolve into a progressive loss of the patient’s autonomy. The absence of a single diagnostic test means that, in many cases, «confirmation of the disease is delayed for months,» according to the authors.
CLINICAL UTILITY
The results of the meta-analysis support theclinical utility of the Gold Coascriteria and «reinforce the evidence accumulated in recent years on their ability to detect more cases of ALS» than some previous diagnostic systems. The researchers consider in their conclusions «thatfaster identification of patients could translate into earlier referral to specialized units and faster incorporation into clinical trials of new treatments.»
The work is also signed by more than twenty international experts, including Parvathi Menon, Matthew Kiernan, Philip van Damme, Leonard van den Berg and Satoshi Kuwabara, leading figures in global research on motor neuron diseases.
